Adocia (ADOC.PA)

Executive Summary

Adocia is a clinical-stage biotechnology company headquartered in Lyon, France, dedicated to developing innovative therapies for diabetes and obesity. Leveraging its proprietary BioChaperone® technology platform, the company designs optimized formulations of approved peptides and proteins, as well as cell-based therapies, to address significant unmet medical needs in chronic metabolic diseases. Its lead programs include BioChaperone Lispro, an ultra-rapid insulin analog, and BioChaperone Glucagon, a stable liquid glucagon formulation, both of which have the potential to improve glycemic control and ease of use for patients. With a focus on product differentiation and patient-centric design, Adocia aims to provide safer and more effective alternatives to existing treatments. The company has advanced its pipeline to Phase 3 clinical trials for BioChaperone Lispro and is progressing Phase 2 studies for BioChaperone Glucagon. In addition, Adocia has established strategic partnerships, including a collaboration with Tonghua Dongbao in China for development and commercialization. Key upcoming milestones include top-line data from the Phase 3 trial of BioChaperone Lispro, which could pave the way for regulatory submissions in Europe and the US. Validation through partnership expansion or positive trial results would significantly de-risk Adocia's technology and enhance its commercial prospects. Given the high unmet need in diabetes and obesity, Adocia's platform holds substantial promise, though execution risks remain typical of clinical-stage biotechs.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Data Readout for BioChaperone Lispro60% success
• Q1 2027Regulatory Submission (EMA/FDA) for BioChaperone Lispro50% success
• TBDNew Partnership or Licensing Deal for BioChaperone Glucagon45% success